ARWR: Countdown to Nov. 18, 2025 PDUFA for Plozasiran for FCS
On August 7, 2025, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for the third quarter of fiscal year 2025 that ended June...
549 Views
ARWR: Multiple Value Drivers for Long-Term Growth
On May 12, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for the second quarter of fiscal year 2025 that ended March...
212 Views
Arrowhead Pharmaceuticals Inc - On February 10
On February 10, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced financial results for the first quarter of fiscal year 2025 that ended...
271 Views
ARWR: License and Collaboration Deal with Sarepta Includes 825 Million Upon Closing
On November 26, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced a global licensing and collaboration agreement with Sarepta Therapeutics...
358 Views
ARWR: PALISADE Phase 3 Results Published in NEJM
On September 2, 2024, Arrowhead Pharmaceuticals, Inc. (ARWR) announced results from the Phase 3 PALISADE study of plozasiran in patients with...
409 Views